“Yiqi Huayu, Wenyang Lishui” Prescription (YHWLP) Improves the Symptoms of Chronic Obstructive Pulmonary Disease-Induced Chronic Pulmonary Heart Disease by Inhibiting the RhoA/ROCK Signaling Pathway

Table 1

Comparison of pulmonary function (after treatment vs. baseline) in each group.

Group		FEV1	FVC	FEV1/FVC	FEV1%
YHWLP (n = 40)	Baseline	1.37 ± 0.45	2.51 ± 0.58	54.20 ± 7.84	56.95 ± 8.82
	After	1.76 ± 0.54	2.90 ± 0.65	60.55 ± 6.19	63.06 ± 9.20
Control (n = 40)	Baseline	1.44 ± 0.45	2.59 ± 0.57	54.46 ± 6.69	57.75 ± 9.68
	After	1.50 ± 0.43	2.70 ± 0.52	56.38 ± 6.73	63.56 ± 8.77

Notes: FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; FEV1%, FEV1 as a percentage of predicted value. Values are mean ± standard deviation. , .